Printer Friendly

MEDTRONIC AGREES TO ACQUIRE CARDIORHYTHM, ENTERS ABLATION MARKET

 MEDTRONIC AGREES TO ACQUIRE CARDIORHYTHM, ENTERS ABLATION MARKET
 MINNEAPOLIS, May 14 /PRNewswire/ -- Medtronic, Inc. (NYSE: MDT) announced today that it had signed a purchase agreement to acquire CardioRhythm, of San Jose, CA, a manufacturer of electrophysiological catheters for the diagnosis and treatment of certain cardiac arrhythmias. Financial terms were not disclosed.
 Commercial release of two CardioRhythm diagnostic catheters, the Torqr(TM) and the Voyagr(TM), was authorized by the U.S. Food and Drug Administration (FDA) on March 9, 1992. These devices aid electrophysiologists in locating the sites of arrhythmias.
 CardioRhythm has applied to the FDA for permission to begin clinical evaluation of the Atakr(TM) RF Catheter Ablation System. This system is designed to use radio frequency energy to ablate, or interrupt, abnormal electrical pathways within the heart muscle, thereby curing arrhythmias.
 "The acquisition of CardioRhythm will give Medtronic an important strategic
entry into the rapidly emerging field of ablation of arrhythmias. Medtronic will be the first company to provide both ablation and implantable device therapeutic options for rapid heartbeat," said William W. George, Medtronic president and chief executive officer. "We expect the market potential of both methods of arrhythmia treatment to be very significant." George said CardioRhythm would operate as a wholly owned subsidiary under the direction of Medtronic's Tachyarrhythmia Management business. Its products will be distributed by the worldwide Medtronic sales force.
 Medtronic estimates the current worldwide market for diagnostic and therapeutic electrophysiological catheters to be in excess of $100 million annually. The total market is expected to reach the $250-300 million range by 1995.
 Medtronic's implantable PCD(TM) staged-therapy device for tachyarrhythmia received unanimous support from a Food and Drug Administration advisory panel on February 3, 1992, and now awaits premarketing approval from the FDA.
 Medtronic, Inc., headquartered in Minneapolis, is a leading developer and manufacturer of biomedical devices for improving cardiovascular and neurological health.
 -0- 5/14/92
 /CONTACT: Dale Beumer, 612-574-3038 or Dick Reid, 612-574-3052, both of Medtronic/
 (MDT) CO: Medtronic, Inc. ST: Minnesota IN: MTC SU: TNM


KH -- MN005 -- 0065 05/14/92 09:29 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 14, 1992
Words:343
Previous Article:ENHANCE FINANCIAL SERVICES GROUP REPORTS FIRST QUARTER EARNINGS
Next Article:PITNEY BOWES SIGNS $15 MILLION AGREEMENT WITH MCI FOR TELECOMMUNICATIONS SERVICES
Topics:


Related Articles
MEDTRONIC COMPLETES ACQUISITION OF CARDIORHYTHM, EXPANDING ITS TACHYARRHYTHMIA BUSINESS
MEDTRONIC ANNOUNCES EXPANSION OF CLINICAL IMPLANTS OF NEW TRANSVENOUS LEAD SYSTEM
FDA ADVISORY PANEL TO CONSIDER MEDTRONIC RF CARDIAC ABLATION SYSTEM AT MEETING DECEMBER 5
FDA ADVISORY PANEL RECOMMENDS APPROVAL OF MEDTRONIC RF CARDIAC ABLATION SYSTEM
MEDTRONIC MOVES TO ACQUIRE SYNECTICS MEDICAL AS BASE TO EXPAND IN NEW BUSINESS AREAS
MEDTRONIC, INSTENT AGREE TO MERGE AND OFFER BROADEST LINE OF STENTS TO WORLD MEDICAL MARKETS
MEDTRONIC FORMS NEW VASCULAR ORGANIZATION, ANNOUNCES EXECUTIVE ASSIGNMENTS
AVECOR Announces Suit by Medtronic.
Medtronic Announces New Venture in Intravascular Radiation Therapy; Acquisition of XRT Corp. Fuels Entry Into Emerging Market.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters